An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical trials. However, this approach is limited to patients without AAV-neutralizing antibodies (NAbs). In this study, we explored the feasibility of AAV re-administration in hemophilia A dogs treated initially 8 ye...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-09-01
|
| Series: | Molecular Therapy: Methods & Clinical Development |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050118300755 |
| _version_ | 1819162559220023296 |
|---|---|
| author | Junjiang Sun Wenwei Shao Xiaojing Chen Elizabeth P. Merricks Lauren Wimsey Yasmina L. Abajas Glenn P. Niemeyer Clinton D. Lothrop Paul E. Monahan R. Jude Samulski Timothy C. Nichols Chengwen Li |
| author_facet | Junjiang Sun Wenwei Shao Xiaojing Chen Elizabeth P. Merricks Lauren Wimsey Yasmina L. Abajas Glenn P. Niemeyer Clinton D. Lothrop Paul E. Monahan R. Jude Samulski Timothy C. Nichols Chengwen Li |
| author_sort | Junjiang Sun |
| collection | DOAJ |
| description | Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical trials. However, this approach is limited to patients without AAV-neutralizing antibodies (NAbs). In this study, we explored the feasibility of AAV re-administration in hemophilia A dogs treated initially 8 years ago with AAV8.canine FVIII. After the re-administration in two NAb-negative dogs with AAV8 vectors carrying human factor VIII (hFVIII), along with the proteasome inhibitor bortezomib, we observed a phenotypic improvement in both dogs that persisted in one dog. Phenotypic improvement disappeared at 59 days after re-administration in the other dog, and specific cytotoxic T lymphocytes (CTLs) to the capsid were detected at day 17, but not to hFVIII. hFVIII inhibitors were observed at day 59 and gradually increased. Mechanistic studies demonstrated an increase in pro-inflammatory cytokines, a decrease in immunomodulatory cytokines, as well as lower Tregs after re-administration. These results suggest that hFVIII inhibitor development may contribute to the therapeutic failure via immune response activation. Interestingly, it takes about 30–50 days for AAV NAb titers to decrease by half. Collectively, this study suggests that re-administration of the same AAV serotype after long-term follow-up is feasible and that the study of AAV NAb kinetics will provide important information for predicating the efficacy of re-administration. Keywords: AAV, hemophilia, neutralizing antibodies, NAbs, re-administration, human factor VIII, hFVIII, hFVIII inhibitor |
| first_indexed | 2024-12-22T17:30:10Z |
| format | Article |
| id | doaj.art-ddd9feb7fb3a4072a978a554d53586c5 |
| institution | Directory Open Access Journal |
| issn | 2329-0501 |
| language | English |
| last_indexed | 2024-12-22T17:30:10Z |
| publishDate | 2018-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Methods & Clinical Development |
| spelling | doaj.art-ddd9feb7fb3a4072a978a554d53586c52022-12-21T18:18:39ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012018-09-0110257267An Observational Study from Long-Term AAV Re-administration in Two Hemophilia DogsJunjiang Sun0Wenwei Shao1Xiaojing Chen2Elizabeth P. Merricks3Lauren Wimsey4Yasmina L. Abajas5Glenn P. Niemeyer6Clinton D. Lothrop7Paul E. Monahan8R. Jude Samulski9Timothy C. Nichols10Chengwen Li11Gene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAGene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAGene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Biochemistry, University of Alabama at Birmingham, Birmingham, AL, USADepartment of Biochemistry, University of Alabama at Birmingham, Birmingham, AL, USAGene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAGene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAGene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Corresponding author: Chengwen Li, Gene Therapy Center, University of North Carolina at Chapel Hill, 104 Manning Dr., Chapel Hill, NC 27599, USA.Adeno-associated virus (AAV) vectors have been successfully applied in hemophilia clinical trials. However, this approach is limited to patients without AAV-neutralizing antibodies (NAbs). In this study, we explored the feasibility of AAV re-administration in hemophilia A dogs treated initially 8 years ago with AAV8.canine FVIII. After the re-administration in two NAb-negative dogs with AAV8 vectors carrying human factor VIII (hFVIII), along with the proteasome inhibitor bortezomib, we observed a phenotypic improvement in both dogs that persisted in one dog. Phenotypic improvement disappeared at 59 days after re-administration in the other dog, and specific cytotoxic T lymphocytes (CTLs) to the capsid were detected at day 17, but not to hFVIII. hFVIII inhibitors were observed at day 59 and gradually increased. Mechanistic studies demonstrated an increase in pro-inflammatory cytokines, a decrease in immunomodulatory cytokines, as well as lower Tregs after re-administration. These results suggest that hFVIII inhibitor development may contribute to the therapeutic failure via immune response activation. Interestingly, it takes about 30–50 days for AAV NAb titers to decrease by half. Collectively, this study suggests that re-administration of the same AAV serotype after long-term follow-up is feasible and that the study of AAV NAb kinetics will provide important information for predicating the efficacy of re-administration. Keywords: AAV, hemophilia, neutralizing antibodies, NAbs, re-administration, human factor VIII, hFVIII, hFVIII inhibitorhttp://www.sciencedirect.com/science/article/pii/S2329050118300755 |
| spellingShingle | Junjiang Sun Wenwei Shao Xiaojing Chen Elizabeth P. Merricks Lauren Wimsey Yasmina L. Abajas Glenn P. Niemeyer Clinton D. Lothrop Paul E. Monahan R. Jude Samulski Timothy C. Nichols Chengwen Li An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs Molecular Therapy: Methods & Clinical Development |
| title | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| title_full | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| title_fullStr | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| title_full_unstemmed | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| title_short | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| title_sort | observational study from long term aav re administration in two hemophilia dogs |
| url | http://www.sciencedirect.com/science/article/pii/S2329050118300755 |
| work_keys_str_mv | AT junjiangsun anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT wenweishao anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT xiaojingchen anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT elizabethpmerricks anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT laurenwimsey anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT yasminalabajas anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT glennpniemeyer anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT clintondlothrop anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT paulemonahan anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT rjudesamulski anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT timothycnichols anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT chengwenli anobservationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT junjiangsun observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT wenweishao observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT xiaojingchen observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT elizabethpmerricks observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT laurenwimsey observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT yasminalabajas observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT glennpniemeyer observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT clintondlothrop observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT paulemonahan observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT rjudesamulski observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT timothycnichols observationalstudyfromlongtermaavreadministrationintwohemophiliadogs AT chengwenli observationalstudyfromlongtermaavreadministrationintwohemophiliadogs |